OLIPASS Corporation (KOSDAQ:244460)

Market Cap	10.18B
Revenue (ttm)	5.25B
Net Income (ttm)	-16.72B
Shares Out	4.39M
EPS (ttm)	-5,043.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,271
Average Volume	195,578
Open	2,125.00
Previous Close	2,160.00
Day's Range	2,120.00 - 2,335.00
52-Week Range	2,085.00 - 9,250.00
Beta	0.34
RSI	35.64
Earnings Date	Mar 21, 2025

About OLIPASS

OLIPASS Corporation, a biotech company, focuses on developing therapeutic products in South Korea. The company develops its products using its novel PNA based technologies. Its products pipeline includes SCN9A, a product candidate that is in Phase II clinical trials for the treatment of pain. The company also develops PCSK9 for the treatment of hyper cholesterolemia; VEGF for the treatment of AMD/DR; HIF-1α for chemo/radio-sensitizer treatment; Dystrophin for the treatment of duchenne muscular disease; and PTP1B for the treatment of type II dia...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 78
• Stock Exchange: KOSDAQ
• Ticker Symbol: 244460

Financial Performance

In 2022, OLIPASS's revenue was 2.30 billion, an increase of 169.56% compared to the previous year's 851.78 million. Losses were -24.17 billion, -3.85% less than in 2021.